Peter S Maclean

Summary

Country: UK

Publications

  1. ncbi request reprint Hereditary and acquired antithrombin deficiency: epidemiology, pathogenesis and treatment options
    Peter S Maclean
    Department of Haematology, Glasgow Royal Infirmary, Glasgow, UK
    Drugs 67:1429-40. 2007
  2. ncbi request reprint Ideal body weight correlates better with engraftment after PBSC autograft than actual body weight, but is under-estimated in myeloma patients possibly due to disease-related height loss
    P S MacLean
    Department of Clinical Apheresis, Scottish National Blood Transfusion Service, Glasgow Royal Infirmary, Scotland, UK
    Bone Marrow Transplant 40:665-9. 2007
  3. doi request reprint Treatment related factors and inhibitor development in children with severe haemophilia A
    P S MacLean
    Haemophilia Centre, Yorkhill Children s Hospital, Glasgow, UK
    Haemophilia 17:282-7. 2011

Collaborators

Detail Information

Publications3

  1. ncbi request reprint Hereditary and acquired antithrombin deficiency: epidemiology, pathogenesis and treatment options
    Peter S Maclean
    Department of Haematology, Glasgow Royal Infirmary, Glasgow, UK
    Drugs 67:1429-40. 2007
    ..A recombinant antithrombin product now under investigation, and recently licensed in Europe, may provide a useful alternative treatment option...
  2. ncbi request reprint Ideal body weight correlates better with engraftment after PBSC autograft than actual body weight, but is under-estimated in myeloma patients possibly due to disease-related height loss
    P S MacLean
    Department of Clinical Apheresis, Scottish National Blood Transfusion Service, Glasgow Royal Infirmary, Scotland, UK
    Bone Marrow Transplant 40:665-9. 2007
    ..We confirm that calculation of CD34+ cell dose by IBW safely predicts engraftment for patients with haematological malignancies other than myeloma undergoing PBSC autograft...
  3. doi request reprint Treatment related factors and inhibitor development in children with severe haemophilia A
    P S MacLean
    Haemophilia Centre, Yorkhill Children s Hospital, Glasgow, UK
    Haemophilia 17:282-7. 2011
    ..This study confirms treatment-related factors as important risks for inhibitor development in Haemophilia A...